Mesoblast Limited vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.25 (market cap $2.45B). The key difference: Energy Fuels Inc Ordinary Shares (Canada) is the larger of the two by market cap, and Mesoblast Limited is more actively traded (259,445 versus 7,967,898). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| MESO | UUUU | |
|---|---|---|
Market Cap | $1.83B | $2.45B |
Volume | 259,445 | 7,967,898 |
Sector | Health | Energy |
52-Week High | $20.96 | $27.72 |
52-Week Low | $13.19 | $8.34 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.91B | $2.19B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →